SecBot SecBot

ASND drug pipeline

Ascendis Pharma A/S · 3 rated drugs
$275.39
+3.1% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±5.7%
1-day, median of 3 events
IV rank
No data
No current options data
Rated drugs
3
1 bullish · 1 mixed · 1 neutral
Phase 3 trials
7
7 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (FDA approval August 2021)

lonapegsomatropin Updated Sep 1

What to watch

Skytrofa is a steady commercial contributor but not the primary value driver for ASND anymore, YORVIPATH's rapid growth and the YUVIWEL launch are the main catalysts. Watch for any FDA filing for adult GHD indication (completed Phase 3 data in hand) and quarterly Skytrofa sales trajectory. The stock's next major binary catalyst is the EU MAA decision for YUVIWEL expected in Q4 2026.

Bull case
  • Once-weekly dosing is a clear convenience advantage over daily somatropin injections, supporting market share gains in pediatric GHD.
  • Skytrofa generated €55M in Q2 2026 revenue as part of ASND's total €315M product revenue (+105% YoY), showing commercial traction.
  • Completed Phase 3 adult GHD trials provide a potential label expansion opportunity that could double the addressable market.
Bear case
  • Skytrofa faces competition from established daily somatropin products (Genotropin, Norditropin) and other long-acting GH products, limiting pricing power.
  • Multiple large institutional holders (FMR, Capital World, Morgan Stanley, Goldman Sachs) fully exited ASND positions in Q2 2026, signaling potential concern about valuation or competitive positioning.
  • Skytrofa is now the #2 product for ASND behind YORVIPATH (€252M vs €55M in Q2), meaning the stock's thesis is less dependent on this drug.
▲ bullish
Impact
PhaseApproved
Time to marketAlready approved and commercially launched in the U.S. (August 2024) and EU (November 2023). Available in over 35 countries.

YORVIPATH palopegteriparatide Updated Sep 12

What to watch

YORVIPATH is already approved and generating substantial revenue, so the binary approval catalyst has passed. Investors should focus on the commercial ramp trajectory (quarterly revenue growth, patient enrollment trends, and international expansion) and watch for any label-expansion catalysts (pediatric hypoparathyroidism). The stock trades at ~$263 with a consensus price target of ~$314 (20% upside) and a Strong Buy analyst consensus.

Bull case
  • First and only FDA-approved treatment for hypoparathyroidism, a rare disease with no other approved drug alternatives after NATPARA was discontinued in late 2024.
  • Rapid commercial ramp: Q2 2026 YORVIPATH revenue of €252M (+145% YoY), with >5,300 US patient enrollments and availability in 35+ countries.
  • Strong analyst consensus: 27 Buy/Strong Buy ratings vs 1 Hold, mean price target $314 (20% upside from ~$263).
Bear case
  • No upcoming binary catalyst, the defining FDA approval event has passed, so stock moves will depend on gradual commercial execution rather than a single catalyst.
  • Hypoparathyroidism is a niche rare disease with a limited addressable patient population, capping peak revenue potential.
  • Pricing and reimbursement risk: as a lifelong treatment for a chronic condition, payer pushback could slow adoption.
◆ mixed
Impact
PhaseApproved (FDA Accelerated Approval, February 2026)
Time to marketAlready approved and commercially available in the US (launched April 2026). EMA approval in Europe is pending with no publicly confirmed date.

YUVIWEL Updated Jun 30

What to watch

The binary approval catalyst has passed. Investors should now watch the commercial ramp (prescription trends, payer access, revenue contribution in upcoming quarterly reports) and any announcement of the confirmatory trial timeline or EMA filing date. The weekly-vs-daily dosing advantage is real, but first-mover BioMarin's Voxzogo ($927M in 2025 sales) is entrenched.

Bull case
  • Once-weekly dosing is a clear convenience advantage over BioMarin's Voxzogo (daily injection), which should drive physician and caregiver preference over time.
  • 7-year orphan drug exclusivity (granted April 2026) blocks competitor market entry, giving Ascendis a protected runway to establish YUVIWEL.
  • Voxzogo generated $927M in revenue in 2025 (up 26% YoY), proving large demand, YUVIWEL only needs partial market share to be material for a company of Ascendis's size.
Bear case
  • Accelerated approval requires a confirmatory trial to verify clinical benefit (final adult height). If that trial fails, FDA could withdraw approval, a long-tail risk with no clear readout date.
  • BioMarin's Voxzogo has first-mover advantage, established brand recognition, and approval down to infancy; YUVIWEL is currently labeled only for ages 2+.
  • BridgeBio's infigratinib (FGFR3 blocker) is in development as an oral drug candidate for achondroplasia, representing a potential future third competitor.

Other drugs in filings and trials

no drug report yet

Past FDA events & how the stock moved

3 events
DateDrugEvent1 day5 days
Feb 27, 2026YUVIWELApproval+5.7%+5.1%
Aug 9, 2024YORVIPATHApproval+2.0%+10.2%
Aug 25, 2021lonapegsomatropinApproval+23.0%+36.1%

Clinical trials

12 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
TransCon TLR7/8 AgonistA Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid TumorsPhase 2Terminated188Dec 2, 2025
lonapegsomatropinA Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone DeficiencyPhase 3Completed · results220Dec 23, 2024
Navepegritide (TransCon CNP)A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With AchondroplasiaPhase 3Completed · results84Aug 9, 2024
lonapegsomatropinA Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone DeficiencyPhase 3Completed · results264Nov 2, 2023
lonapegsomatropinA Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical TrialPhase 3Completed · results298Feb 21, 2023
TransCon CNPA Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With AchondroplasiaPhase 2Completed · results57Sep 27, 2022
—A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With HypoparathyroidismPhase 3Completed · results84Jan 12, 2022
—A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With HypoparathyroidismPhase 2Completed · results59Mar 6, 2020
lonapegsomatropinA Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone DeficiencyPhase 3Completed · results146Mar 19, 2019
Once weekly subcutaneous injection of TransCon hGHA Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)Phase 3Completed · results162Jan 17, 2019
ACP-001Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)Phase 2Completed · results53Jul 2015
lonapegsomatropinA Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone DeficiencyPhase 2Completed · results37May 2011